IMPACT Therapeutics has received the China NMPA marketing authorisation for Senaparib capsules in treating ovarian cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback